How many drug targets are there?
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
For the past decade, the number of molecular targets for approved drugs has been debated. Here, we reconcile apparently contradictory previous reports into a comprehensive survey, and propose a consensus number of current drug targets for all classes of approved therapeutic drugs. One striking feature is the relatively constant historical rate of target innovation (the rate at which drugs against new targets are launched); however, the rate of developing drugs against new families is significantly lower. The recent approval of drugs that target protein kinases highlights two additional trends: an emerging realization of the importance of polypharmacology, and also the power of a gene-family-led approach in generating novel and important therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, G-protein-coupled receptors (GPCRs) are influenced by trafficking progress and then internalized in the cell membrane and recycled or degraded.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
In the citing paper
“Covalent molecules may not be able to effectively target GPCRs during this turnover process [127].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The Pfam Protein Families Database
Bateman, A. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.276 · Cited by 14,000
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Murzin, A. G., Brenner, S. E., Hubbard, T., & Chothia, C. (1995) · Journal of Molecular Biology · doi:10.1016/s0022-2836(05)80134-2 · Cited by 7,012 · cited 1×
“Patterns in drug targets In order to identify the familial relationships between all drug targets, we analysed the presence of domains, using the SCO”
MethodDrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“drugs acted primarily through only 120 underlying molecular target”
BackgroundSelf-citationThe Pfam protein families database
Bateman, A. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh121 · Cited by 3,127
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967 · cited 1×
“Imatinib, originally developed as a highly selective inhibitor of c-AB”
BackgroundA small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892 · cited 1×
“(and which target association led to its first approval for chronic myeloid leukaemia), has subsequently been discovered to be have significant activity against several other clinically relevant kinases, such as c-KI”
Background
Research works printed but not linked: 1
- Christensen, C. M. The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail (Harvard Business School Press, Cambridge, 1997).
Cited by
Items 201–300 of 1,024
Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin
Albers, J., Keller, J., Baranowsky, A., Beil, F. T., Catala-Lehnen, P., Schulze, J., Amling, M., & Schinke, T. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201207142 · Cited by 186
The systematic analysis of protein–lipid interactions comes of age
Saliba, A.-E., Vonkova, I., & Gavin, A.-C. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4080 · Cited by 189
“thermophilum)41 Arachidonoyl lipid-interacting proteins identified using chemically engineered lipids (human)60 13 lipid-transfer proteins tested for their ability to interact with lipids using affinity-purification lipidomics (yeast)23 374 genes implicated in plasma membrane biology by genetic interaction assays (yea…”
BackgroundMethodInfluentialComputational Multitarget Drug Design
Zhang, W., Pei, J., & Lai, L. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00491 · Cited by 180
PROTACs to address the challenges facing small molecule inhibitors
Martín-Acosta, P., & Xiao, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112993 · Cited by 172
In silico drug repositioning – what we need to know
Liu, Z., Fang, H., Reagan, K., Xu, X., Mendrick, D. L., Slikker, W., & Tong, W. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.08.005 · Cited by 183
Metabotropic receptors for glutamate and GABA in pain
Goudet, C., Magnaghi, V., Landry, M., Nagy, F., Gereau, R. W., & Pin, J.-P. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.007 · Cited by 188
“As a result, GPCRs are involved in the regulation of many physiological or pathological processes and are the target of about a quarter of drugs available on the market (Overington et al., 2006).”
BackgroundEpigallocatechin Gallate Inactivates Clinical Isolates of Herpes Simplex Virus
Isaacs, C. E., Wen, G. Y., Xu, W., Jia, J. H., Rohan, L., Corbo, C., Di Maggio, V., Jenkins, E. C., & Hillier, S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00825-07 · Cited by 183
“sequences (32) and is recognized by EGCG.”
Lindsley, C. W., Emmitte, K. A., Hopkins, C. R., Bridges, T. M., Gregory, K. J., Niswender, C. M., & Conn, P. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00656 · Cited by 181
How Chemoproteomics Can Enable Drug Discovery and Development
Moellering, R. E., & Cravatt, B. F. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.001 · Cited by 182
“Each protein target, owing to its distinct structure and function, presents a special set of challenges for chemical probe development, and many have argued that only a small fraction of the human proteome is even, in principle, ‘druggable’ [7, 8].”
BackgroundErratum: Mechanistic enzymology in drug discovery: a fresh perspective
Holdgate, G. A., Meek, T. D., & Grimley, R. L. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.257 · Cited by 180
Identifying mechanism-of-action targets for drugs and probes
Gregori-Puigjané, E., Setola, V., Hert, J., Crews, B. A., Irwin, J. J., Lounkine, E., Marnett, L., Roth, B. L., & Shoichet, B. K. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204524109 · Cited by 182
Segala, E., Guo, D., Cheng, R. K. Y., Bortolato, A., Deflorian, F., Doré, A. S., Errey, J. C., Heitman, L. H., IJzerman, A. P., Marshall, F. H., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00653 · Cited by 184
“drugs.(1) Recent advances in GPCR structural biology have enabled the visualization of”
BackgroundAn atlas of nano-enabled neural interfaces
Acarón Ledesma, H., Li, X., Carvalho-de-Souza, J. L., Wei, W., Bezanilla, F., & Tian, B. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0487-x · Cited by 178
Evaluating drug targets through human loss-of-function genetic variation
Minikel, E. V., Karczewski, K. J., Martin, H. C., Cummings, B. B., Whiffin, N., Rhodes, D., Alföldi, J., Trembath, R. C., van Heel, D. A., Daly, M. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2267-z · Cited by 187
The mouse sperm proteome characterized via IPG strip prefractionation and LC‐MS/MS identification
Baker, M. A., Hetherington, L., Reeves, G. M., & Aitken, R. J. (2008) · PROTEOMICS · doi:10.1002/pmic.200701020 · Cited by 178
Ahlbach, C. L., Lexa, K. W., Bockus, A. T., Chen, V., Crews, P., Jacobson, M. P., & Lokey, R. S. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.78 · Cited by 178
Fauman, E. B., Rai, B. K., & Huang, E. S. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.05.020 · Cited by 181
Discovery and development of natural product oridonin-inspired anticancer agents
Ding, Y., Ding, C., Ye, N., Liu, Z., Wold, E. A., Chen, H., Wild, C., Shen, Q., & Zhou, J. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.06.015 · Cited by 178
Steroid hormones in the aquatic environment
Ojoghoro, J. O., Scrimshaw, M. D., & Sumpter, J. P. (2021) · Science of The Total Environment · doi:10.1016/j.scitotenv.2021.148306 · Cited by 173
Warr, W. A. (2009) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-009-9260-9 · Cited by 176
1,2,3-Triazole tethered β-lactam-Chalcone bifunctional hybrids: Synthesis and anticancer evaluation
Singh, P., Raj, R., Kumar, V., Mahajan, M. P., Bedi, P. M. S., Kaur, T., & Saxena, A. K. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.10.033 · Cited by 177
What are nuclear receptor ligands?
Sladek, F. M. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.06.018 · Cited by 175
Mechanisms of Protein Kinase A Anchoring
(2010) · International Review of Cell and Molecular Biology · doi:10.1016/s1937-6448(10)83005-9 · Cited by 175
Expanding the Number of ‘Druggable’ Targets: Non‐Enzymes and Protein–Protein Interactions
Makley, L. N., & Gestwicki, J. E. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12066 · Cited by 176
Membrane Protein–Lipid Interactions Probed Using Mass Spectrometry
Bolla, J. R., Agasid, M. T., Mehmood, S., & Robinson, C. V. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111508 · Cited by 173
Drugs for ‘protein clouds’: targeting intrinsically disordered transcription factors
Dunker, A. K., & Uversky, V. N. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.09.005 · Cited by 174
Schröder, R., Schmidt, J., Blättermann, S., Peters, L., Janssen, N., Grundmann, M., Seemann, W., Kaufel, D., Merten, N., Drewke, C., et al. (2011) · Nature Protocols · doi:10.1038/nprot.2011.386 · Cited by 173
“Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes.”
BackgroundLehár, J., Stockwell, B. R., Giaever, G., & Nislow, C. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.120 · Cited by 172
Chen, Z., Liang, X., Zhang, H., Xie, H., Liu, J., Xu, Y., Zhu, W., Wang, Y., Wang, X., Tan, S., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100025u · Cited by 171
Veldhuis, N. A., Poole, D. P., Grace, M., McIntyre, P., & Bunnett, N. W. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009555 · Cited by 172
“They are receptors for structurally diverse endogenous and exogenous ligands, participate in all pathophysiological processes, and are established therapeutic targets, with 30% of current drugs targeting GPCRs (Overington et al., 2006).”
BackgroundInfluentialNew insights from structural biology into the druggability of G protein-coupled receptors
Mason, J. S., Bortolato, A., Congreve, M., & Marshall, F. H. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.02.005 · Cited by 170
Community benchmarks for virtual screening
Irwin, J. J. (2008) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-008-9189-4 · Cited by 171
“Comprehensive coverage of every possible binding site situation and pharmaceutical target class [34] is impractical because such a benchmark would be too big and unwieldy; it is also unrealistic for two practical reasons.”
BackgroundTargeting heparin and heparan sulfate protein interactions
Weiss, R. J., Esko, J. D., & Tor, Y. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob01058c · Cited by 172
A network medicine approach to human disease
Zanzoni, A., Soler-López, M., & Aloy, P. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.03.001 · Cited by 171
“…: non-GPCR receptors, the 8%; ion channels : the 7%; transporters : the 4%; and others : targets which are not classified under any of the families mentioned above, the 4%. genes are currently targeted by marketed drugs [67], which leaves plenty of room for development of drugs against new targets.”
BackgroundRapid Measurement of Intracellular Unbound Drug Concentrations
Mateus, A., Matsson, P., & Artursson, P. (2013) · Molecular Pharmaceutics · doi:10.1021/mp4000822 · Cited by 168
Structure-inspired design of β-arrestin-biased ligands for aminergic GPCRs
McCorvy, J. D., Butler, K. V., Kelly, B., Rechsteiner, K., Karpiak, J., Betz, R. M., Kormos, B. L., Shoichet, B. K., Dror, R. O., Jin, J., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2527 · Cited by 170
“G protein-coupled receptors (GPCRs), which form the largest target class in the druggable genome, are crucial for nearly every physiological process 1 .”
Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance
Shahar, N., & Larisch, S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100712 · Cited by 165
The Best of Both Worlds? Bitopic Orthosteric/Allosteric Ligands of G Protein–Coupled Receptors
Valant, C., Robert Lane, J., Sexton, P. M., & Christopoulos, A. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134514 · Cited by 168
β-Adrenergic receptor subtype signaling in heart: From bench to bedside
Woo, A. Y. H., & Xiao, R.-P. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.201 · Cited by 168
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders
Wong, T., Li, G., Li, S., Gao, W., Chen, G., Gan, S., Zhang, M., Li, H., Wu, S., & Du, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01427-2 · Cited by 198
Drug‐Target Residence Time—A Case for G Protein‐Coupled Receptors
Guo, D., Hillger, J. M., IJzerman, A. P., & Heitman, L. H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21307 · Cited by 166
Bosc, N., Atkinson, F., Felix, E., Gaulton, A., Hersey, A., & Leach, A. R. (2019) · Journal of Cheminformatics · doi:10.1186/s13321-018-0325-4 · Cited by 165
A tool kit of highly selective and sensitive genetically encoded neuropeptide sensors
Wang, H., Qian, T., Zhao, Y., Zhuo, Y., Wu, C., Osakada, T., Chen, P., Chen, Z., Ren, H., Yan, Y., et al. (2023) · Science · doi:10.1126/science.abq8173 · Cited by 153
Glycolytic enzyme inhibitors in cancer treatment
Scatena, R., Bottoni, P., Pontoglio, A., Mastrototaro, L., & Giardina, B. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.10.1533 · Cited by 164
“Recently, synthesis of some phosphoenolpyruvate (PEP) analogs with modifications in the phosphate and the carboxylate function have been described [100,101] .”
BackgroundDocking-based inverse virtual screening: methods, applications, and challenges
Xu, X., Huang, M., & Zou, X. (2018) · Biophysics Reports · doi:10.1007/s41048-017-0045-8 · Cited by 165
“…the G-protein-coupled receptors (GPCRs), is one of the most important targets in drug design, given the fact that they account for over a quarter of the known drug targets (Overington et al. 2006), and about half of the drugs on the market target GPCRs specifically (Klabunde and Hessler 2002).”
BackgroundIdentification of the cellular targets of bioactive small organic molecules using affinity reagents
Leslie, B. J., & Hergenrother, P. J. (2008) · Chemical Society Reviews · doi:10.1039/b702942j · Cited by 165
Kiss, M., Czimmerer, Z., & Nagy, L. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.05.044 · Cited by 161
“The importance of nuclear receptor–regulated pathways in maintaining a physiologic state is best illustrated by the fact that approximately 13% of US Food and DrugAdministration (FDA)– approved drugs target one of the 48 known human nuclear receptors.(33) RXR heterodimers, as described in this review, are also targets…”
BackgroundEndothelial TWIK-related potassium channel-1 (TREK1) regulates immune-cell trafficking into the CNS
Bittner, S., Ruck, T., Schuhmann, M. K., Herrmann, A. M., Maati, H. M. O., Bobak, N., Göbel, K., Langhauser, F., Stegner, D., Ehling, P., et al. (2013) · Nature Medicine · doi:10.1038/nm.3303 · Cited by 166
Cabral-Marques, O., Marques, A., Giil, L. M., De Vito, R., Rademacher, J., Günther, J., Lange, T., Humrich, J. Y., Klapa, S., Schinke, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07598-9 · Cited by 162
Protein folding and de novo protein design for biotechnological applications
Khoury, G. A., Smadbeck, J., Kieslich, C. A., & Floudas, C. A. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.10.008 · Cited by 161
How to design multi-target drugs: target search options in cellular networks
Korcsmáros, T., Szalay, M. S., Böde, C., Kovács, I. A., & Csermely, P. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.6.799 · Cited by 155
“However, despite all the considerable drug development efforts undertaken, the number of successful drugs and novel targets fell significantly behind the expectations during past decades [1-3] .”
BackgroundRNA therapy: Are we using the right molecules?
Yu, A.-M., Jian, C., Yu, A. H., & Tu, M.-J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.011 · Cited by 163
Network-based drug repositioning
Wu, Z., Wang, Y., & Chen, L. (2013) · Molecular BioSystems · doi:10.1039/c3mb25382a · Cited by 162
The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism
Wootten, D., Reynolds, C. A., Smith, K. J., Mobarec, J. C., Koole, C., Savage, E. E., Pabreja, K., Simms, J., Sridhar, R., Furness, S. G. B., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.023 · Cited by 164
“G protein-coupled receptors (GPCRs) are critical for the transmission of extracellular signals across the cell membrane to initiate intracellular responses (Fredriksson et al., 2003) and are the leading targets of currently marketed therapeutics (Overington et al., 2006).”
BackgroundMolecular Parameters of siRNA–Cell Penetrating Peptide Nanocomplexes for Efficient Cellular Delivery
van Asbeck, A. H., Beyerle, A., McNeill, H., Bovee-Geurts, P. H. M., Lindberg, S., Verdurmen, W. P. R., Hällbrink, M., Langel, Ü., Heidenreich, O., & Brock, R. (2013) · ACS Nano · doi:10.1021/nn305754c · Cited by 160
“drugs and at present only a limited number of pathophysiologically relevant proteins can be targetted.(1) With the discovery of siRNA and miRNA, strategies to specifically target pathogenic proteins on the posttranscriptional level have emerged.”
BackgroundZocher, M., Zhang, C., Rasmussen, S. G. F., Kobilka, B. K., & Müller, D. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210373109 · Cited by 154
“subtypes? Biochem Pharmacol 48(6):1059–1071.”
Tero, R. (2012) · Materials · doi:10.3390/ma5122658 · Cited by 154
“These SLB devices are expected as a powerful tool for the analysis of membrane proteins, which account for roughly half of the targets of drug discovery [33].”
“Molecular Switches” on mGluR Allosteric Ligands That Modulate Modes of Pharmacology
Wood, M. R., Hopkins, C. R., Brogan, J. T., Conn, P. J., & Lindsley, C. W. (2011) · Biochemistry · doi:10.1021/bi200129s · Cited by 153
Expression, Regulation and Putative Nutrient-Sensing Function of Taste GPCRs in the Heart
Foster, S. R., Porrello, E. R., Purdue, B. W., Chan, H., Voigt, A., Frenzel, S., Hannan, R. D., Moritz, K. M., Simmons, D. G., Molenaar, P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064579 · Cited by 177
“Not surprisingly, mutations and modifications of GPCRs, G proteins and their regulatory partners are linked to dysfunction and disease, with an estimated 40% of all drugs on the market eliciting their activity through GPCRs [2].”
BackgroundMelatonin: A review of its potential functions and effects on neurological diseases
Günata, M., Parlakpınar, H., & Acet, A. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2019.07.025 · Cited by 171
Investigation of stable and transient protein–protein interactions: Past, present, and future
Wetie, A. G. N., Sokolowska, I., Woods, A. G., Roy, U., Loo, J. A., & Darie, C. C. (2013) · PROTEOMICS · doi:10.1002/pmic.201200328 · Cited by 174
Laraia, L., McKenzie, G., Spring, D. R., Venkitaraman, A. R., & Huggins, D. J. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.04.019 · Cited by 148
“Assay Platforms for HTS Screening methods for inhibiting PPIs vary depending on the overall approach taken (Pagliaro et al., 2004).”
He, B., Zhao, Y., Xu, L., Gao, L., Su, Y., Lin, N., & Pu, J. (2016) · Journal of Pineal Research · doi:10.1111/jpi.12312 · Cited by 163
“Nuclear hormone receptors (NRs) are a family of transcription factors with diverse physiological functions including regulation of metabolism, immune reaction, and stress responses [4, 6, 7] and are the molecular targets of approximately 13% of drugs currently approved by the FDA, highlighting their tractability for t…”
BackgroundROR nuclear receptors: Structures, related diseases, and drug discovery
Zhang, Y., Luo, X.-Y., Wu, D.-H., & Xu, Y. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.120 · Cited by 151
An Integrated Framework Advancing Membrane Protein Modeling and Design
Alford, R. F., Koehler Leman, J., Weitzner, B. D., Duran, A. M., Tilley, D. C., Elazar, A., & Gray, J. J. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004398 · Cited by 156
“They comprise more than 30% of open reading frames [2] and are targeted by over half of currently available pharmaceutical drugs [3,4].”
BackgroundSilver-Based Nanoparticles Induce Apoptosis in Human Colon Cancer Cells Mediated Through P53
Satapathy, S. R., Mohapatra, P., Preet, R., Das, D., Sarkar, B., Choudhuri, T., Wyatt, M. D., & Kundu, C. N. (2013) · Nanomedicine · doi:10.2217/nnm.12.176 · Cited by 151
Saponins as modulators of nuclear receptors
Zhang, T., Zhong, S., Li, T., & Zhang, J. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1514580 · Cited by 153
“Among these molecular targets, glucocorticoid receptor is targeted with the most number of drug substances (Overington, Al-Lazikani, and Hopkins 2006).”
BackgroundHebling, C. M., Morgan, C. R., Stafford, D. W., Jorgenson, J. W., Rand, K. D., & Engen, J. R. (2010) · Analytical Chemistry · doi:10.1021/ac100962c · Cited by 150
Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key
Haupt, V. J., Daminelli, S., & Schroeder, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065894 · Cited by 147
“Important drug targets like GPCRs and other membrane proteins [34] are underrepresented in the PDB due to their hydrophobic nature.”
BackgroundInfluentialGLASS: a comprehensive database for experimentally validated GPCR-ligand associations
Chan, W. K. B., Zhang, H., Yang, J., Brender, J. R., Hur, J., Özgür, A., & Zhang, Y. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv302 · Cited by 146
“A new textmining algorithm was proposed to collect GPCR-ligand interactions from the biomedical literature, which is then crosschecked with five primary pharmacological datasets, to enhance the coverage and accuracy of GPCR-ligand association data identifications.”
MethodGPCRDB: an information system for G protein-coupled receptors
Isberg, V., Vroling, B., van der Kant, R., Li, K., Vriend, G., & Gloriam, D. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1255 · Cited by 151
“GPCRs are major targets for the pharmaceutical industry, as reflected by the fact that more than a quarter of all FDA-approved drugs act on a GPCR (1).”
BackgroundTargeting the Undruggable Proteome: The Small Molecules of My Dreams
Crews, C. M. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.05.011 · Cited by 147
Automated Parallel Recordings of Topologically Identified Single Ion Channels
Kawano, R., Tsuji, Y., Sato, K., Osaki, T., Kamiya, K., Hirano, M., Ide, T., Miki, N., & Takeuchi, S. (2013) · Scientific Reports · doi:10.1038/srep01995 · Cited by 149
Ehsanian, R., Waes, C. V., & Feller, S. M. (2011) · Cell Communication and Signaling · doi:10.1186/1478-811x-9-13 · Cited by 151
“eral clinical effects, is an exciting and developing area of cancer research [91].”
BackgroundAre GPCRs Still a Source of New Targets?
Garland, S. L. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113498418 · Cited by 184
“The G-proteins are typically classified into four families based on the sequence similarity of the α subunit: (1) Gαs, which stimulates cAMP production; (2) Gαi, which inhibits cAMP production; (3) Gαq/11, which leads to intracellular calcium mobilization; and (4) Gα12/13, which actives the monomeric GTPase RhoA.”
BackgroundSpracklen, C. N., Chen, P., Kim, Y. J., Wang, X., Cai, H., Li, S., Long, J., Wu, Y., Wang, Y. X., Takeuchi, F., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx062 · Cited by 148
“G-protein coupled receptors (GPCR) are commonly used as therapeutic targets, particularly in the treatment of dyslipidemia (43).”
BackgroundDouble-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways
Dey, A., Tergaonkar, V., & Lane, D. P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2759 · Cited by 170
“Polypharmacology has been the term used for drugs that bind to and modulate multiple targets thereby contributing to their various clinical effect”
BackgroundEngineering mid-infrared nanoantennas for surface enhanced infrared absorption spectroscopy
Adato, R., Aksu, S., & Altug, H. (2015) · Materials Today · doi:10.1016/j.mattod.2015.03.001 · Cited by 159
Kamal, A., Prabhakar, S., Ramaiah, M. J., Reddy, P. V., Reddy, C. R., Mallareddy, A., Shankaraiah, N., Reddy, T. L. N., Pushpavalli, S. N. C. V. L., & Pal‐Bhadra, M. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.05.050 · Cited by 156
Bauer, R. A., Wurst, J. M., & Tan, D. S. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.02.001 · Cited by 148
Predicting Binding Affinities for GPCR Ligands Using Free-Energy Perturbation
Lenselink, E. B., Louvel, J., Forti, A. F., van Veldhoven, J. P. D., de Vries, H., Mulder-Krieger, T., McRobb, F. M., Negri, A., Goose, J., Abel, R., et al. (2016) · ACS Omega · doi:10.1021/acsomega.6b00086 · Cited by 142
Tanaka, Y., Suetsugu, Y., Yamamoto, K., Noda, H., & Shinoda, T. (2013) · Peptides · doi:10.1016/j.peptides.2013.07.027 · Cited by 154
Wetie, A. G. N., Sokolowska, I., Woods, A. G., Roy, U., Deinhardt, K., & Darie, C. C. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1333-1 · Cited by 165
“Second, it is not applicable to full-length integral membrane proteins, which represent the first class of therapeutic targets [39].”
Applications of Molecular Dynamics Simulation in Protein Study
Sinha, S., Tam, B., & Wang, S. M. (2022) · Membranes · doi:10.3390/membranes12090844 · Cited by 173
Receptor-Mediated Activation of Heterotrimeric G-Proteins: Current Structural Insights
Johnston, C. A., & Siderovski, D. P. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.034348 · Cited by 145
“Indeed, GPCRs represent a major therapeutic target, giving rise to the largest single fraction of the prescription drug market, with annual sales of several billion dollars (Overington et al., 2006).”
BackgroundMembrane protein synthesis in cell‐free systems: From bio‐mimetic systems to bio‐membranes
Sachse, R., Dondapati, S. K., Fenz, S. F., Schmidt, T., & Kubick, S. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.06.007 · Cited by 168
“Thus, it is not a coincidence that they form the major group of pharmaceutical targets [1–3].”
BackgroundHennen, S., Wang, H., Peters, L., Merten, N., Simon, K., Spinrath, A., Blättermann, S., Akkari, R., Schrage, R., Schröder, R. J., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004350 · Cited by 156
“A class of membrane proteins with great success as targets for smallmolecule ligand discovery is the family A G protein (heterotrimeric guanine nucleotide–binding protein)–coupled receptors (GPCRs) (12, 13).”
BackgroundBiological applications of knowledge graph embedding models
Mohamed, S. K., Nounu, A., & Nováček, V. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa012 · Cited by 143
Design, synthesis and biological evaluation of nuclear receptor-degradation inducers
Itoh, Y., Kitaguchi, R., Ishikawa, M., Naito, M., & Hashimoto, Y. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.09.041 · Cited by 148
Targeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 158
Old friends in new guise: repositioning of known drugs with structural bioinformatics
Haupt, V. J., & Schroeder, M. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr011 · Cited by 153
“drugs [22].”
Integration of fragment screening and library design
Siegal, G., Eiso, A. B., & Schultz, J. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.005 · Cited by 142
Wei, D., Jiang, X., Zhou, L., Chen, J., Chen, Z., He, C., Yang, K., Liu, Y., Pei, J., & Lai, L. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8010096 · Cited by 143
Mass spectrometry based tools to investigate protein–ligand interactions for drug discovery
Pacholarz, K. J., Garlish, R. A., Taylor, R. J., & Barran, P. E. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35035a · Cited by 141
West, G. M., Chien, E. Y. T., Katritch, V., Gatchalian, J., Chalmers, M. J., Stevens, R. C., & Griffin, P. R. (2011) · Structure · doi:10.1016/j.str.2011.08.001 · Cited by 140
A Bright Future for Serial Femtosecond Crystallography with XFELs
Johansson, L. C., Stauch, B., Ishchenko, A., & Cherezov, V. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.06.007 · Cited by 149
“Membrane proteins, which comprise about a third of the human proteome and represent targets for almost two thirds of marketed drugs [78, 79], are notoriously difficult to crystallize due in part to their amphiphilic nature and their inherent flexibility.”
BackgroundLow Affinity GPCRs for Metabolic Intermediates: Challenges for Pharmacologists
Smith, N. J. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00001 · Cited by 135
“Indeed, ligands for GPCRs currently account for ∼30% of FDAapproved pharmaceuticals (Overington et al., 2006).”
BackgroundYuan, Q., Gao, J., Wu, D., Zhang, S., Mamitsuka, H., & Zhu, S. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw244 · Cited by 148
“Furthermore, there exist a huge number of unexplored compounds and human proteins, which makes it impossible to examine their interactions effectively by experimental approaches.”
BackgroundProperties of Protein Drug Target Classes
Bull, S. C., & Doig, A. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0117955 · Cited by 135
“found that over 50% of drugs target GPCRs, nuclear receptors or ion channels [6]; Hopkins and Groom found that enzymes comprise 47% of launched targets, while GPCRs account for 30% [1]; and Zheng et al.”
BackgroundDesign of Cyclic Peptides That Bind Protein Surfaces with Antibody-Like Affinity
Millward, S. W., Fiacco, S. V., Austin, R. J., & Roberts, R. W. (2007) · ACS Chemical Biology · doi:10.1021/cb7001126 · Cited by 137
“GPCRs are clinically important, and a large fraction of marketed drugs target these receptors (8).”
Background
Metadata
- Authors
- Overington, J. P., Al-Lazikani, B., & Hopkins, A. L.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Overington, John P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-12
- Volume
- 5
- Issue
- 12
- Pages
- 993-996
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1968682237
- Cited by
- 3,505
- References
- 29
- Citations by year
- 2026: 82 · 2025: 126 · 2024: 117 · 2023: 127 · 2022: 173 · 2021: 168 · 2020: 190 · 2019: 190 · 2018: 198 · 2017: 215 · 2016: 276 · 2015: 268 · 2014: 245 · 2013: 280 · 2012: 247
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- therapeutic target, molecular targets, protein kinases, polypharmacology, approved drugs
- MeSH terms
- Humans, Technology, Pharmaceutical, Drug Design, Drugs, Investigational, Genome, Human, Drug Delivery Systems, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.